Roche (ROG) adds lesion and brain-volume data to fenebrutinib's MS case
New conference analyses explore the candidate's effects beyond relapses as regulatory review continues.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
Roche presented additional fenebrutinib analyses at MSToronto, examining chronic active lesions, brain-volume loss and disability progression in multiple sclerosis. The findings build on the Phase 3 programme supporting its application in relapsing and primary progressive disease.
The company reported reductions in measures of chronic lesion activity and a 23% reduction in annual total brain-volume loss. Pooled relapsing-MS data showed a numerical 16% reduction in 12-week composite confirmed disability progression.
These outcomes address different aspects of disease and should not be merged into a single claim of proven disability prevention. In particular, a numerical difference needs to be interpreted with its statistical context, while imaging findings are distinct from direct measures of patient function.
For Roche, the commercial argument is that an oral BTK inhibitor could address needs beyond relapse control. The new analyses add detail to that proposition, but fenebrutinib remains subject to regulatory assessment. Its eventual place in treatment will depend on the full benefit-risk profile and clinicians' assessment of the approved evidence.